European Patent Office
80298 MUNICH
GERMANY
Tel.: +49 89 2399 - 0
Fax: +49 89 2399 - 4465

Europäisches Patentamt | European Patent Office | Office européen des brevets

Lucas, Phillip Brian
Lucas & Co.
135 Westhall Road
Warlingham, Surrey CR6 9HJ
GRANDE BRETAGNE

EPO Customer Services
Tel.: +31 (0)70 340 45 00

Date: 31.01.07

Reference	Application No./Patent No.
SLWK1941.001EP1	05776434.2 - 2101 PCT/US2005012028

Applicant/Proprietor: Samaritan Pharmaceuticals, Inc., et al

Notification of European publication number and information on the application of Article 67(3) EPC

The provisional protection under Article 67(1) and (2) EPC in the individual contracting states becomes effective only when the conditions referred to in Article 67(3) EPC have been fulfilled (for further details, see information brochure of the European Patent Office "National Law relating to the EPC" and additional information in the Official Journal of the European Patent Office).

Pursuant to Article 158(1) EPC the publication under Article 21 PCT of an international application for which the European Patent Office is a designated Office takes the place of the publication of a European patent application.

The bibliographic data of the above-mentioned Euro-PCT application will be published on 28.02.07 in Section I.1 of the European Patent Bulletin. The European publication number is 1755605.

In all future communications to the European Patent Office, please quote the application number plus Directorate number.

Receiving Section

Europäisches Patentamt • European Patent Office • Office européen des brevets

P.B.5818 - Patentlaan 2
2280 HV Rijswijk (ZH)
(070) 3 40 20 40
FAX (070) 3 40 30 16

Europäisches Patentamt | European Patent Office | Office européen des brevets

Generaldirektion 1 | Directorate General 1 | Direction générale 1

Lucas, Phillip Brian
Lucas & Co.
135 Westhall Road
Warlingham, Surrey CR6 9HJ
GRANDE BRETAGNE

EPO Customer Services
Tel.: +31 (0)70 340 45 00

Date 18-01-2007

Reference	Application No./Patent No.
SLWK1941.001EP1	05776434.2 - 2107 PCT/US2005012028

Applicant/Proprietor
Samaritan Pharmaceuticals, Inc., et al

Communication pursuant to Rules 109 and 110 EPC

(1) Amendment of application documents, especially the claims (R. 109 EPC)

The above mentioned international (Euro-PCT) application has entered the European phase, or can do so, once the necessary conditions are fulfilled.

Under Articles 28, 41 PCT, Rules 52, 78 PCT and Rule 86(2) to (4) EPC, the applicant may amend the application documents after receiving the international search report.

Whether or not he has already done so, he now has a further opportunity to file amended claims or other application documents within a non-extendable time limit of one month after notification of the present communication (R. 109 EPC).

The claims applicable on expiry of the above time limit, i.e. those filed on entry into the European phase or in response to the present communication, will form the basis for the calculation of any claims fee to be paid (see page 2) and for any supplementary search to be carried out under Article 157(2) EPC (R. 109 EPC).

--2/

(2) Claims fees under Rule 110 EPC

If the application documents on which the European grant procedure is to be based comprise more than ten claims, a claims fee shall be payable for the eleventh and each subsequent claim within the period provided for in Rule 107(1) EPC.

☑ Based on the application documents currently on file, all necessary claims fees have already been paid (or the documents do not comprise more than 10 claims).

☐ All necessary fees will be/have been debited automatically according to the automatic debit order.

☐ The claims fee due for the claims ..... to ..... were not paid within the above-mentioned period.

Any non-paid claims fee, either based on the current set of claims or on any amended claims to be filed pursuant to Rule 109 EPC (see page 1), may still be validly paid within a non-extendable period of grace of **one month** after notification of this communication.

If a payment is made for only some of the claims, it must be indicated for which claims it is intended. If a claims fee is not paid in due time, the claim concerned is deemed to be abandoned (R. 110(4) EPC).

If claims fees have already been paid, but on expiry of the above-mentioned time limit there is a new set of claims containing fewer fee-incurring claims than previously, the claims fees in excess of those due under Rule 110(2), 2nd sentence, EPC will be refunded (R. 110(3) EPC).

You are reminded that any supplementary search under Article 157(2) EPC will relate only to the last set of claims applicable on expiry of the above time limit AND will be confined to those fee-incurring claims for which fees have been paid in due time.

The fee for the eleventh and each subsequent claim is EUR 45,00.

Receiving Section

Europäisches Patentamt • European Patent Office • Office européen des brevets

P.B.5818 - Patentlaan 2
2280 HV Rijswijk (ZH)
Tel. (070) 3 40 20 40
FAX (070) 3 40 30 16

Europäisches Patentamt	European Patent Office	Office européen des brevets
Generaldirektion 1	Directorate General 1	Direction générale 1

Lucas, Phillip Brian
Lucas & Co.
135 Westhall Road
Warlingham, Surrey CR6 9HJ
GRANDE BRETAGNE

EPO Customer Services
Tel.: +31 (0)70 340 45 00

Date
13.12.06

Reference	Application No./Patent No.
SLWK1941.001EP1	05776434.2-2107-US2005012028

Applicant/Proprietor
Samaritan Pharmaceuticals, Inc., et al

Refund of fees

The following fees were paid in respect of the application 05776434.2:

Fee	Code	Voucher No	Date	Currency	Amount
Search fee	002	00702270	10.11.06	EUR	576,00

REFUND ORDER

1. According to Art. 157(3)a) EPC no supplementary search report is drawn up (see also OJ EPO 1994, 691 and 1995, 511).

2. The refund will be done by:
CREDITING THE DEPOSIT ACCOUNT 28050111.

Amount refundable:	Code	Currency	Amount	Voucher No
	002	EUR	576,00	00747931
Total:		**EUR**	**576,00**	

The Authorising Officer
Adams
(49)(89)23992668

Europäisches Patentamt • European Patent Office • Office européen des brevets

Munich

LUCAS & CO.
Chartered Patent Agents
European Patent Attorneys

135 WESTHALL ROAD
WARLINGHAM
SURREY CR6 9HJ
ENGLAND

Telephones: 01883-626211

Fax: INT+44+1883+622997
e-mail: mail@lucas-uk.com

CONFIRMATION OF FAX

EPO - Munich
29

10th November 2006

13. Nov. 2006

The European Patent Office
PB5818 Patentlaan 2
NL-2280 HV Rijswijk
Netherlands

Dear Sirs

Re: European Patent Application No. 05 776 434.2 based on
PCT Patent Application No. PCT/US2005/012028
(Filed 12th April 2005) claiming priority from
US Patent Application No. 60/562,643
(Filed 15th April 2004)
Applicants: Samaritan Pharmaceuticals, Inc.; and
Georgetown University
Inventors: LECANU, L.; GREESON, J.; PAPADOPOULOS, V.
"Use of (4-Alkylpiper Azinyl) (Phenyl) Methanones in the
Treatment of Alzheimer's Disease"
Case: SLWK 1941.001EP1

BY FAX

We have been instructed to act on behalf of **Samaritan Pharmaceuticals, Inc. and Georgetown University** in the prosecution of the European Regional Phase of this application.

We are instructed that the Applicant wishes to proceed in all available states which we believe are: Austria, Belgium, Bulgaria, Switzerland (including Liechtenstein), Cyprus, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, UK, Greece, Hungary, Ireland, Iceland, Italy, Lithuania, Luxembourg, Monaco, the Netherlands, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia and Turkey.

We have today sent a copy of this letter to your Cash & Accounts department in Munich, together with a fee sheet instructing them to deduct the sum of EUR **2976.00** from our Deposit Account No. 28050111 to cover:-

Zur Kasse

1. National Fee;
2. Designation Fees (Max 7);
3. Search fee (80% i.e. Euro 576);
4. Substantive Examination Fee (100% i.e. Euro 1490); and
5. Additional claims fee (4).

contn:-

Since this case has a filing date before 1st July 2005 an Official Search fee of Euro 720 applies. However, we have only paid 80% of the Official Search fee as the International Search was carried out by the U.S. Searching Authority.

An examination fee of Euro 1490 also applies. We have paid the full Substantive Examination fee as International Preliminary Examination was not carried out by the European Patent Office.

Would you please accept this letter as our formal request for Substantive Examination of this application which should be carried out on the basis of the claims enclosed.

Would you please return the attached copy of this letter to acknowledge safe receipt hereof.

Yours faithfully

Brian Lucas

Brian Lucas/gar
Chartered Patent Agent
European Patent Attorney

Enc: Fee sheet (Munich)
New claims

Records:- SLWK 1941.001EP1

Status - 24 Nov 06

WHAT IS CLAIMED IS:

1. Use of a compound of formula I:



(I)

wherein:

a) R^1, R^2 and R^3 are individually H, OH, halo, $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, $(C_3\text{-}C_6)$cycloalkyl, $(C_3\text{-}C_6)$cycloalkyl($(C_1\text{-}C_6)$alkyl), $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, $(C_1\text{-}C_6)$alkanoyl, halo$(C_1\text{-}C_6)$alkyl, hydroxy$(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxycarbonyl, $(C_1\text{-}C_6)$alkylthio, thio$(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkanoyloxy, $N(R^6)(R^7)$ wherein R^6 and R^7 are individually H, O, $(C_1\text{-}C_6)$ alkyl, $(C_3\text{-}C_6)$cycloalkyl, $(C_3\text{-}C_6)$cycloalkyl$(C_1\text{-}C_6)$alkyl, phenyl or benzyl, or R^6 and R^7, together with the N to which they are attached form a 5- or 6-membered ring, optionally comprising 1-2 S, $N(R^6)$ or nonperoxide O, or R^1 and R^2 together are methylenedioxy;

b) Y and Z together are =O, $-O(CH_2)_mO-$ or $-(CH_2)_m-$ wherein m is 2-4, or Y is H and Z is OR^9 or SR^9, wherein R^9 is H or $(C_1\text{-}C_4)$alkyl;

c) X is $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, hydroxyl$(C_1\text{-}C_6)$alkyl $(C_3\text{-}C_{12})$alkenyl, $(C_2\text{-}C_6)$alkynyl, carboxy, $(C_1\text{-}C_6)$alkoxycarbonyl, thio$(C_1\text{-}C_6)$ alkyl, $(C_3\text{-}C_{12})$heterocyclo, $(C_3\text{-}C_{12})$ heterocycloalkyl$(C_1\text{-}C_6)$ alkyl, aryl or heteroaryl, optionally substituted by 1, 2 or 3 R^1;

or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a mammal threatened or afflicted by Alzheimer's disease.

2. The use of claim 1 wherein the medicament is for inhibiting Aβ peptide-induced neurotoxicity preferably $A\beta_{1\text{-}42}$ neurotoxicity.

3. The use of claim 1 wherein the medicament is for inhibiting glutamate-induced neurotoxicity in said mammal.

4. The use of any one of claims 1-3 wherein the mammal is a human.

5. The use of any one of claims 1-4 wherein R^1, R^2 or R^3 is $N(R^6)(R^7)$.

6. The use of any one of claims 1-5 wherein R^2 is $(C_1–C_6)$alkoxy.

7. The use of any one of claims 1-6 wherein R^3 is $(C_1–C_6)$alkoxy.

8. The use of any one of claims 1-4 or 6 or 7 wherein each of R^1, R^2 and R^3 is (C_1-C_3)alkoxy.

9. The use of any one of claims 1-8 wherein Y and Z together are =O.

10. The use of any one of claims 1-8 wherein Y is H and Z is OH.

11. The use of any one of claims 1-10 wherein X is $(C_1–C_6)$alkyl.

12. The use of any one of claims 1-11 wherein X is CH_3.

13. The use of claim 1 wherein the compound of formula I is [(2,3,4-trimethoxy)phenyl]-[4-ethylpiperazin-1-yl] methanone.

14. A composition comprising a compound of formula (I) as defined in claim 1 in combination with a pharmaceutically-acceptable carrier.

Hague

LUCAS & CO.
Chartered Patent Agents
European Patent Attorneys

135 WESTHALL ROAD
WARLINGHAM
SURREY CR6 9HJ
ENGLAND

Telephones: 01883-626211

Fax: INT+44+1883+622997
e-mail: mail@lucas-uk.com

10th November 2006

The European Patent Office
PB5818 Patentlaan 2
NL-2280 HV Rijswijk
Netherlands

EPO - DG 1

13. 11. 2006

(65)

Dear Sirs

Re: European Patent Application No. 05 776 434.2 based on
PCT Patent Application No. PCT/US2005/012028
(Filed 12th April 2005) claiming priority from
US Patent Application No. 60/562,643
(Filed 15th April 2004)
Applicants: Samaritan Pharmaceuticals, Inc.; and
Georgetown University
Inventors: LECANU, L.; GREESON, J.; PAPADOPOULOS, V.
"Use of (4-Alkylpiper Azinyl) (Phenyl) Methanones in the
Treatment of Alzheimer's Disease"
Case: SLWK 1941.001EP1

BY FAX

We have been instructed to act on behalf of **Samaritan Pharmaceuticals, Inc. and Georgetown University** in the prosecution of the European Regional Phase of this application.

We are instructed that the Applicant wishes to proceed in all available states which we believe are: Austria, Belgium, Bulgaria, Switzerland (including Liechtenstein), Cyprus, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, UK, Greece, Hungary, Ireland, Iceland, Italy, Lithuania, Luxembourg, Monaco, the Netherlands, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia and Turkey.

We have today sent a copy of this letter to your Cash & Accounts department in Munich, together with a fee sheet instructing them to deduct the sum of EUR **2976.00** from our Deposit Account No. 28050111 to cover:-

1. National Fee;
2. Designation Fees (Max 7);
3. Search fee (80% i.e. Euro 576);
4. Substantive Examination Fee (100% i.e. Euro 1490); and
5. Additional claims fee (4).

contn:-

Since this case has a filing date before 1st July 2005 an Official Search fee of Euro 720 applies. However, we have only paid 80% of the Official Search fee as the International Search was carried out by the U.S. Searching Authority.

An examination fee of Euro 1490 also applies. We have paid the full Substantive Examination fee as International Preliminary Examination was not carried out by the European Patent Office.

Would you please accept this letter as our formal request for Substantive Examination of this application which should be carried out on the basis of the claims enclosed.

Would you please return the attached copy of this letter to acknowledge safe receipt hereof.

Yours faithfully

Brian Lucas

Brian Lucas/gar
Chartered Patent Agent
European Patent Attorney

Enc: Fee sheet (Munich)
New claims

Records:- SLWK 1941.001EP1

Status - 24 Nov 06

WHAT IS CLAIMED IS:

1. Use of a compound of formula I:



(I)

wherein:

a) R^1, R^2 and R^3 are individually H, OH, halo, $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, $(C_3\text{-}C_6)$cycloalkyl, $(C_3\text{-}C_6)$cycloalkyl($(C_1\text{-}C_6)$alkyl), $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, $(C_1\text{-}C_6)$alkanoyl, halo$(C_1\text{-}C_6)$alkyl, hydroxy$(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxycarbonyl, $(C_1\text{-}C_6)$alkylthio, thio$(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkanoyloxy, N(R^6)(R^7) wherein R^6 and R^7 are individually H, O, $(C_1\text{-}C_6)$ alkyl, $(C_3\text{-}C_6)$cycloalkyl, $(C_3\text{-}C_6)$cycloalkyl$(C_1\text{-}C_6)$alkyl, phenyl or benzyl, or R^6 and R^7, together with the N to which they are attached form a 5- or 6-membered ring, optionally comprising 1-2 S, N(R^6) or nonperoxide O, or R^1 and R^2 together are methylenedioxy;

b) Y and Z together are =O, $-O(CH_2)_mO-$ or $-(CH_2)_m-$ wherein m is 2-4, or Y is H and Z is OR^9 or SR^9, wherein R^9 is H or $(C_1\text{-}C_4)$alkyl;

c) X is $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, hydroxyl$(C_1\text{-}C_6)$alkyl $(C_3\text{-}C_{12})$alkenyl, $(C_2\text{-}C_6)$alkynyl, carboxy, $(C_1\text{-}C_6)$alkoxycarbonyl, thio$(C_1\text{-}C_6)$ alkyl, $(C_3\text{-}C_{12})$heterocyclo, $(C_3\text{-}C_{12})$ heterocycloalkyl$(C_1\text{-}C_6)$ alkyl, aryl or heteroaryl, optionally substituted by 1, 2 or 3 R^1;

or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a mammal threatened or afflicted by Alzheimer's disease.

2. The use of claim 1 wherein the medicament is for inhibiting Aβ peptide-induced neurotoxicity preferably $A\beta_{1\text{-}42}$ neurotoxicity.

3. The use of claim 1 wherein the medicament is for inhibiting glutamate-induced neurotoxicity in said mammal.

4. The use of any one of claims 1-3 wherein the mammal is a human.

5. The use of any one of claims 1-4 wherein R^1, R^2 or R^3 is $N(R^6)(R^7)$.

6. The use of any one of claims 1-5 wherein R^2 is $(C_1–C_6)$alkoxy.

7. The use of any one of claims 1-6 wherein R^3 is $(C_1–C_6)$alkoxy.

8. The use of any one of claims 1-4 or 6 or 7 wherein each of R^1, R^2 and R^3 is (C_1-C_3)alkoxy.

9. The use of any one of claims 1-8 wherein Y and Z together are =O.

10. The use of any one of claims 1-8 wherein Y is H and Z is OH.

11. The use of any one of claims 1-10 wherein X is $(C_1–C_6)$alkyl.

12. The use of any one of claims 1-11 wherein X is CH_3.

13. The use of claim 1 wherein the compound of formula I is [(2,3,4-trimethoxy)phenyl]-[4-ethylpiperazin-1-yl] methanone.

14. A composition comprising a compound of formula (I) as defined in claim 1 in combination with a pharmaceutically-acceptable carrier.

Hague

LUCAS & CO.
Chartered Patent Agents
European Patent Attorneys

135 WESTHALL ROAD
WARLINGHAM
SURREY CR6 9HJ
ENGLAND

Fax: INT+44+1883+622997
e-mail: mail@lucas-uk.com

Telephones: 01883-626211

10th November 2006

The European Patent Office
PB5818 Patentlaan 2
NL-2280 HV Rijswijk
Netherlands

Dear Sirs

Re: European Patent Application No. 05 776 434.2 based on
PCT Patent Application No. PCT/US2005/012028
(Filed 12th April 2005) claiming priority from
US Patent Application No. 60/562,643
(Filed 15th April 2004)
Applicants: Samaritan Pharmaceuticals, Inc.; and
Georgetown University
Inventors: LECANU, L.; GREESON, J.; PAPADOPOULOS, V.
"Use of (4-Alkylpiper Azinyl) (Phenyl) Methanones in the Treatment of Alzheimer's Disease"
Case: SLWK 1941.001EP1

BY FAX

We have been instructed to act on behalf of **Samaritan Pharmaceuticals, Inc. and Georgetown University** in the prosecution of the European Regional Phase of this application.

We are instructed that the Applicant wishes to proceed in all available states which we believe are: Austria, Belgium, Bulgaria, Switzerland (including Liechtenstein), Cyprus, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, UK, Greece, Hungary, Ireland, Iceland, Italy, Lithuania, Luxembourg, Monaco, the Netherlands, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia and Turkey.

We have today sent a copy of this letter to your Cash & Accounts department in Munich, together with a fee sheet instructing them to deduct the sum of EUR 2976.00 from our Deposit Account No. 28050111 to cover:-

1. National Fee;
2. Designation Fees (Max 7);
3. Search fee (80% i.e. Euro 576);
4. Substantive Examination Fee (100% i.e. Euro 1490); and
5. Additional claims fee (4).

contn:-

Since this case has a filing date before 1st July 2005 an Official Search fee of Euro 720 applies. However, we have only paid 80% of the Official Search fee as the International Search was carried out by the U.S. Searching Authority.

An examination fee of Euro 1490 also applies. We have paid the full Substantive Examination fee as International Preliminary Examination was not carried out by the European Patent Office.

Would you please accept this letter as our formal request for Substantive Examination of this application which should be carried out on the basis of the claims enclosed.

Would you please return the attached copy of this letter to acknowledge safe receipt hereof.

Yours faithfully

Brian Lucas/gar
Chartered Patent Agent
European Patent Attorney

Enc: Fee sheet (Munich)
New claims

Records:- SLWK 1941.001EP1

Status - 24 Nov 06

WHAT IS CLAIMED IS:

1. Use of a compound of formula I:



(I)

wherein:

a) R^1, R^2 and R^3 are individually H, OH, halo, $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, $(C_3\text{-}C_6)$cycloalkyl, $(C_3\text{-}C_6)$cycloalkyl($(C_1\text{-}C_6)$alkyl), $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, $(C_1\text{-}C_6)$alkanoyl, halo$(C_1\text{-}C_6)$alkyl, hydroxy$(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxycarbonyl, $(C_1\text{-}C_6)$alkylthio, thio$(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkanoyloxy, $N(R^6)(R^7)$ wherein R^6 and R^7 are individually H, O, $(C_1\text{-}C_6)$ alkyl, $(C_3\text{-}C_6)$cycloalkyl, $(C_3\text{-}C_6)$cycloalkyl$(C_1\text{-}C_6)$alkyl, phenyl or benzyl, or R^6 and R^7, together with the N to which they are attached form a 5- or 6-membered ring, optionally comprising 1-2 S, $N(R^6)$ or nonperoxide O, or R^1 and R^2 together are methylenedioxy;

b) Y and Z together are =O, $-O(CH_2)_mO-$ or $-(CH_2)_m-$ wherein m is 2-4, or Y is H and Z is OR^9 or SR^9, wherein R^9 is H or $(C_1\text{-}C_4)$alkyl;

c) X is $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, hydroxyl$(C_1\text{-}C_6)$alkyl $(C_3\text{-}C_{12})$alkenyl, $(C_2\text{-}C_6)$alkynyl, carboxy, $(C_1\text{-}C_6)$alkoxycarbonyl, thio$(C_1\text{-}C_6)$ alkyl, $(C_3\text{-}C_{12})$heterocyclo, $(C_3\text{-}C_{12})$ heterocycloalkyl$(C_1\text{-}C_6)$ alkyl, aryl or heteroaryl, optionally substituted by 1, 2 or 3 R^1;

or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a mammal threatened or afflicted by Alzheimer's disease.

2. The use of claim 1 wherein the medicament is for inhibiting Aβ peptide-induced neurotoxicity preferably $A\beta_{1\text{-}42}$ neurotoxicity.

3. The use of claim 1 wherein the medicament is for inhibiting glutamate-induced neurotoxicity in said mammal.

4. The use of any one of claims 1-3 wherein the mammal is a human.

5. The use of any one of claims 1-4 wherein R^1, R^2 or R^3 is $N(R^6)(R^7)$.

6. The use of any one of claims 1-5 wherein R^2 is $(C_1–C_6)$alkoxy.

7. The use of any one of claims 1-6 wherein R^3 is $(C_1–C_6)$alkoxy.

8. The use of any one of claims 1-4 or 6 or 7 wherein each of R^1, R^2 and R^3 is $(C_1$-$C_3)$alkoxy.

9. The use of any one of claims 1-8 wherein Y and Z together are =O.

10. The use of any one of claims 1-8 wherein Y is H and Z is OH.

11. The use of any one of claims 1-10 wherein X is $(C_1–C_6)$alkyl.

12. The use of any one of claims 1-11 wherein X is CH_3.

13. The use of claim 1 wherein the compound of formula I is [(2,3,4-trimethoxy)phenyl]-[4-ethylpiperazin-1-yl] methanone.

14. A composition comprising a compound of formula (I) as defined in claim 1 in combination with a pharmaceutically-acceptable carrier.

Munich

LUCAS & CO.
Chartered Patent Agents
European Patent Attorneys

135 WESTHALL ROAD
WARLINGHAM
SURREY CR6 9HJ
ENGLAND

Fax: INT+44 1883 622997
e-mail: mail@lucas-uk.com

Telephones: 01883-626211

10th November 2006

The European Patent Office
PB5818 Patentlaan 2
NL-2280 HV Rijswijk
Netherlands

Dear Sirs

Re: European Patent Application No. 05 776 434.2 based on
PCT Patent Application No. PCT/US2005/012028
(Filed 12th April 2005) claiming priority from
US Patent Application No. 60/562,643
(Filed 15th April 2004)
Applicants: Samaritan Pharmaceuticals, Inc.; and
Georgetown University
Inventors: LECANU, L.; GREESON, J.; PAPADOPOULOS, V.
"Use of (4-Alkylpiper Azinyl) (Phenyl) Methanones in the
Treatment of Alzheimer's Disease"
Case: SLWK 1941.001EP1

BY FAX

We have been instructed to act on behalf of **Samaritan Pharmaceuticals, Inc. and Georgetown University** in the prosecution of the European Regional Phase of this application.

We are instructed that the Applicant wishes to proceed in all available states which we believe are: Austria, Belgium, Bulgaria, Switzerland (including Liechtenstein), Cyprus, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, UK, Greece, Hungary, Ireland, Iceland, Italy, Lithuania, Luxembourg, Monaco, the Netherlands, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia and Turkey.

We have today sent a copy of this letter to your Cash & Accounts department in Munich, together with a fee sheet instructing them to deduct the sum of **EUR 2976.00** from our Deposit Account No. 28050111 to cover:-

1. National Fee;
2. Designation Fees (Max 7);
3. Search fee (80% i.e. Euro 576);
4. Substantive Examination Fee (100% i.e. Euro 1490); and
5. Additional claims fee (4).

contn:-

Since this case has a filing date before 1st July 2005 an Official Search fee of Euro 720 applies. However, we have only paid 80% of the Official Search fee as the International Search was carried out by the U.S. Searching Authority.

An examination fee of Euro 1490 also applies. We have paid the full Substantive Examination fee as International Preliminary Examination was not carried out by the European Patent Office.

Would you please accept this letter as our formal request for Substantive Examination of this application which should be carried out on the basis of the claims enclosed.

Would you please return the attached copy of this letter to acknowledge safe receipt hereof.

Yours faithfully

Brian Lucas/gar
Chartered Patent Agent
European Patent Attorney

Enc: Fee sheet (Munich)
New claims

Records:- SLWK 1941.001EP1

Status - 24 Nov 06

WHAT IS CLAIMED IS:

1. Use of a compound of formula I:



(I)

wherein:

a) R^1, R^2 and R^3 are individually H, OH, halo, $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, $(C_3$-$C_6)$cycloalkyl, $(C_3$-$C_6)$cycloalkyl$((C_1$-$C_6)$alkyl), $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl, $(C_1$-$C_6)$alkanoyl, halo$(C_1$-$C_6)$alkyl, hydroxy$(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxycarbonyl, $(C_1$-$C_6)$alkylthio, thio$(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkanoyloxy, $N(R^6)(R^7)$ wherein R^6 and R^7 are individually H, O, $(C_1$-$C_6)$ alkyl, $(C_3$-$C_6)$cycloalkyl, $(C_3$-$C_6)$cycloalkyl$(C_1$-$C_6)$alkyl, phenyl or benzyl, or R^6 and R^7, together with the N to which they are attached form a 5- or 6-membered ring, optionally comprising 1-2 S, $N(R^6)$ or nonperoxide O, or R^1 and R^2 together are methylenedioxy;

b) Y and Z together are =O, $-O(CH_2)_mO-$ or $-(CH_2)_m-$ wherein m is 2-4, or Y is H and Z is OR^9 or SR^9, wherein R^9 is H or $(C_1$-$C_4)$alkyl;

c) X is $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, hydroxyl$(C_1$-$C_6)$alkyl $(C_3$-$C_{12})$alkenyl, $(C_2$-$C_6)$alkynyl, carboxy, $(C_1$-$C_6)$alkoxycarbonyl, thio$(C_1$-$C_6)$ alkyl, $(C_3$-$C_{12})$heterocyclo, $(C_3$-$C_{12})$ heterocycloalkyl$(C_1$-$C_6)$ alkyl, aryl or heteroaryl, optionally substituted by 1, 2 or 3 R^1;

or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a mammal threatened or afflicted by Alzheimer's disease.

2. The use of claim 1 wherein the medicament is for inhibiting Aβ peptide-induced neurotoxicity preferably $A\beta_{1-42}$ neurotoxicity.

3. The use of claim 1 wherein the medicament is for inhibiting glutamate-induced neurotoxicity in said mammal.

4. The use of any one of claims 1-3 wherein the mammal is a human.

5. The use of any one of claims 1-4 wherein R^1, R^2 or R^3 is $N(R^6)(R^7)$.

6. The use of any one of claims 1-5 wherein R^2 is $(C_1–C_6)$alkoxy.

7. The use of any one of claims 1-6 wherein R^3 is $(C_1–C_6)$alkoxy.

8. The use of any one of claims 1-4 or 6 or 7 wherein each of R^1, R^2 and R^3 is (C_1-C_3)alkoxy.

9. The use of any one of claims 1-8 wherein Y and Z together are =O.

10. The use of any one of claims 1-8 wherein Y is H and Z is OH.

11. The use of any one of claims 1-10 wherein X is $(C_1–C_6)$alkyl.

12. The use of any one of claims 1-11 wherein X is CH_3.

13. The use of claim 1 wherein the compound of formula I is [(2,3,4-trimethoxy)phenyl]-[4-ethylpiperazin-1-yl] methanone.

14. A composition comprising a compound of formula (I) as defined in claim 1 in combination with a pharmaceutically-acceptable carrier.

Payment of fees and costs

COPY

Zur Kasse

Fax: (+49-89) 2399-2528 (only for matters relating to accounts)

Please complete in typescript only

Name of payer

01 LUCAS, Brian Ronald Esq.
LUCAS & Co.

Address

135 Westhall Road
Warlingham, Surrey CR6 9HJ
02 ENGLAND

Payer's reference: SLWK 1036.093EP1

Mode of payment
- [ ] Bank/giro transfer[1]
- [ ] Enclosed cheque No.
- [x] Debit from deposit account with the EPO is requested[2]

Bank/giro office

Deposit account No.: 28050111

Patent application / patent No. (please use a separate form for each application)

03 EP 05 776 434.2 PCT PCT/US2005/012028 03

	Code		Currency	Amount
04	001	Filing fee	EUR	
05	002	Search fee	EUR	576.00
06	005	Designation fee(s)[3]	EUR	560.00
07	015	Claims fee(s) (Rule 31(1) EPC)	EUR	180.00
08	055	Additional copy	EUR	
09	006	Examination fee	EUR	1,490.00
10	007	Fee for grant including fee for printing (up to 35 pages)	EUR	
11	008	Additional fee for printing (more than 35 pages)	EUR	
12	033	Renewal fee for the 3rd year	EUR	
13	034	Renewal fee for the 4th year	EUR	
14	035	Renewal fee for the 5th year	EUR	
15		Extension fee(s) for[4]:	EUR	
16		020 National Basic Fee	EUR	170.00
17			EUR	
18			EUR	
19			EUR	
20			EUR	
21			EUR	
22		Total	EUR	2,976.00

Signature

Warlingham, GB - 10th November 2006
Place, date

EPO Form 1010 02.06 Explanations 1-4 see overleaf